SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-039830
Filing Date
2023-11-22
Accepted
2023-11-22 08:26:03
Documents
14
Period of Report
2023-11-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K blcm-20231122.htm   iXBRL 8-K 49443
2 EX-2.1 ex21assetpurchaseagreement.htm EX-2.1 522834
  Complete submission text file 0001628280-23-039830.txt   808847

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT blcm-20231122.xsd EX-101.SCH 2158
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT blcm-20231122_def.xml EX-101.DEF 14823
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT blcm-20231122_lab.xml EX-101.LAB 28857
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT blcm-20231122_pre.xml EX-101.PRE 15465
8 EXTRACTED XBRL INSTANCE DOCUMENT blcm-20231122_htm.xml XML 2540
Mailing Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098
Business Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098 (832) 384-1100
BELLICUM PHARMACEUTICALS, INC (Filer) CIK: 0001358403 (see all company filings)

IRS No.: 201450200 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36783 | Film No.: 231430022
SIC: 2834 Pharmaceutical Preparations